On-Device AI Healthcare Company Noul Becomes First Korean Diagnostic Company to Join Swiss Malaria Group

As Noul's malaria diagnostic solution, miLab™ MAL was introduced as 'an innovative product that will enter scale-up level' in Unitaid's 2022 Annual Report, it is getting attention from the international community as an innovative malaria diagnostic solution that overcomes the limitation of rapid diagnostic testing and manual microscopic diagnosis. According to the results of a clinical study of a total of 1,649 patients in Ethiopia and Ghana, unveiled in October 2023 at the American Academy of Tropical Medicine and Hygiene (ASTMH), miLab™ MAL showed significantly higher sensitivity and specificity in diagnosis of P. falciparum and P. vivax malaria compared to field microscopy test. It also showed high applicability in diagnosing parasites with the pfhrp2/3 deletions.
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

As Noul's malaria diagnostic solution, miLab™ MAL was introduced as 'an innovative product that will enter scale-up level' in Unitaid's 2022 Annual Report, it is getting attention from the international community as an innovative malaria diagnostic solution that overcomes the limitation of rapid diagnostic testing and manual microscopic diagnosis. According to the results of a clinical study of a total of 1,649 patients in Ethiopia and Ghana, unveiled in October 2023 at the American Academy of Tropical Medicine and Hygiene (ASTMH), miLab™ MAL showed significantly higher sensitivity and specificity in diagnosis of P. falciparum and P. vivax malaria compared to field microscopy test. It also showed high applicability in diagnosing parasites with the pfhrp2/3 deletions.

Dr. Taehwan Kim, Managing Director of noul GmbH said, "noul GmbH will play a pivotal role in global malaria diagnosis through its activities as a member of the Swiss Malaria Group. By utilizing Noul's innovative malaria diagnostic solution, we are going to further expand our presence in the market by leading strategies to eliminate global malaria and strengthening global cooperation with other group members."

Swiss Malaria Group said, "Noul's innovative diagnostic tools align perfectly with the Swiss Malaria Group's emphasis on innovative solutions in the fight against malaria. Noul, which focuses on diagnostic solutions in blood and tissue diagnostics, has developed a cutting-edge digital microscopy-based malaria diagnostic tool, miLab™ MAL."

Noul Website: https://noul.kr/en/

On-Device AI Healthcare Company Noul Becomes First Korean Diagnostic Company to Join Swiss Malaria Group

Swiss Malaria Group Website: https://www.swissmalariagroup.ch/en/

#SwissMalariaGroup #SMG #Noul #malaria #miLab #AI #innovation

 

Photo - https://mma.prnewswire.com/media/2335030/Photo__Noul_and_SMG.jpg 
Logo - https://mma.prnewswire.com/media/1854227/Noul_logo1_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/on-device-ai-healthcare-company-noul-becomes-first-korean-diagnostic-company-to-join-swiss-malaria-group-302057096.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili
;